San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... ·...
Transcript of San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... ·...
![Page 1: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/1.jpg)
Mike Dixon
Edinburgh Breast Unit
Breakthrough Research Breast Unit Edinburgh
San Antonio Breast Cancer Symposium
Update
![Page 2: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/2.jpg)
Surgical Removal Of Primary Tumor And Axillary
Lymph Nodes In Women With Metastatic Breast
Cancer At First Presentation :
A Randomized Controlled Trial
PI: R A Badwe
Professor Surgical Oncology(Breast)
Tata Memorial Centre Mumbai , India
Co-Investigators V Parmar, R Hawaldar , N Nair, R Kaushik, S Siddique, A Nawle,
A Budrukkar, I Mittra, S Gupta
![Page 3: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/3.jpg)
Background
• Many recent publications have shown survival
advantage for surgery in Stage IV disease
Benefit of Surgery persists in multivariate analyses
• NOT all series have shown benefit
• Fisher’s animal experiment showed growth of
metastases when primary tumour excised
• Value of Surgery in Stage IV disease uncertain
![Page 4: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/4.jpg)
Aim of Study
• To assess effect of removal of primary tumour on
overall survival in women presenting with metastatic
breast cancer
• Sample size Calculation
Baseline median Survival 18 Months
Expected Improvement 6 months
α = 0.05, 1- β = 80%
N = 350
![Page 5: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/5.jpg)
Trial Schema
R MBC
Anthracyclines +/-
Taxanes
(CR /PR ) No Loco-
Regional
Treatment Stratification
Site of Metastasis
Visceral ,
Bone ,
Visceral + Bone
No of Metastasis
<= 3 ,
>3
ER/PgR:
Positive
Negative
NO Trastuzumab Given to HER2 positive patients
![Page 6: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/6.jpg)
Trial Schema
Randomization
(N=350)
*Loco-regional Therapy : BCT / MRM + supraclavicular node clearance if indicated
** Tamoxifen if pre menopausal +AI in Post menopausal / post Oophorectomy
Loco-regional Treatment (#173)
No Loco-regional Treatment (#177)
LR Surgery* +/-
Ovarian Ablation (40)
Radiotherapy + Hormone Therapy in
Hormone sensitive tumors** (84)
Hormone Therapy (96) whenever indicated including
Ovarian Ablation (34)
![Page 7: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/7.jpg)
Stratification
NO LRT (#177)
N (%)
LRT (#173)
N (%)
TOTAL
Site of Metastasis
Bone
Visceral
Bone + Visceral
50 (50.0)
77 (50.7)
50 (51.0)
50 (50.0)
75 (49.3)
48 (49.0)
100
98
152
![Page 8: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/8.jpg)
Stratification
NO LRT (#177)
N (%)
LRT (#173)
N (%)
TOTAL
Site of Metastasis
Bone
Visceral
Bone + Visceral
50 (50.0)
77 (50.7)
50 (51.0)
50 (50.0)
75 (49.3)
48 (49.0)
100
98
152
No. of Metastasis
<= 3
>3
45 (50.6)
132 (50.6)
44 (49.4)
129 (49.4)
89
261
![Page 9: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/9.jpg)
Stratification
NO LRT (#177)
N (%)
LRT (#173)
N (%)
TOTAL
Site of Metastasis
Bone
Visceral
Bone + Visceral
50 (50.0)
77 (50.7)
50 (51.0)
50 (50.0)
75 (49.3)
48 (49.0)
100
98
152
No. of Metastasis
<= 3
>3
45 (50.6)
132 (50.6)
44 (49.4)
129 (49.4)
89
261
ER/PgR
Positive
Negative
106 (51.0)
71 (50.0)
102 (49.0)
71 (50.0)
208
142
![Page 10: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/10.jpg)
Stratification
NO LRT (#177)
N (%)
LRT (#173)
N (%)
TOTAL
Site of Metastasis
Bone
Visceral
Bone + Visceral
50 (50.0)
77 (50.7)
50 (51.0)
50 (50.0)
75 (49.3)
48 (49.0)
100
98
152
No. of Metastasis
<= 3
>3
45 (50.6)
132 (50.6)
44 (49.4)
129 (49.4)
89
261
ER/PgR
Positive
Negative
106 (51.0)
71 (50.0)
102 (49.0)
71 (50.0)
208
142
Age (Median) 47 48 47
Menopausal status
Pre
Post
88 (54.3)
89 (47.3)
74 (45.7)
99 (52.7)
162
186
![Page 11: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/11.jpg)
NO LRT
(177)
LRT
(173)
TOTAL
Protocol
Violations
3 (1.7%) 9 (5.2%) 12
Palliative
Mastectomy
(per protocol)
18 (10.2%) 1 (0.6%) 19
Treatment Anomalies
![Page 12: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/12.jpg)
p =0.004
Overall Survival
![Page 13: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/13.jpg)
Sub Group Analysis
![Page 14: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/14.jpg)
First Progression Local
![Page 15: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/15.jpg)
First Progression Metastatic
![Page 16: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/16.jpg)
Conclusions
• Loco-regional treatment did not confer any survival
advantage and hence should not be offered as a
routine practice in women presenting with MBC
• The lack of survival benefit is due to a trade off
between local control and distant disease
progression
• Removal of the primary tumor conferred a growth
advantage on distant metastasis
![Page 17: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/17.jpg)
Atilla Soran, Vahit Ozmen, Serdar Ozbas, Hasan Karanlık, Mahmut
Muslumanoglu, Abdullah Igci, Zafer Canturk, Zafer Utkan, Cihangir Ozaslan,
Turkkan Evrensel, Cihan Uras, Erol Aksaz, Aykut Soyder, Umit Ugurlu, Cavit
Col, Neslihan Cabioğlu, Betül Bozkurt, Temel Dagoglu, Ali Uzunkoy, Mustafa
Dulger, Neset Koksal, Omer Cengiz, Bahadir Gulluoglu, Bulent Unal, Can Atalay,
Emin Yıldırım, Ergun Erdem, Semra Salimoglu, Atakan Sezer, Ayhan Koyuncu,
Gunay Gurleyik, Haluk Alagol, Nalan Ulufi, Uğur Berberoğlu, Elizabeth D
Kennard, Sheryl Kelsey, Barry Lembersky.
On behalf of the Turkish Federation of Societies
for Breast Diseases
ClinicalTrials.gov identifier number:NCT00557986.
Early follow up of a randomized trial evaluating
Resection of the Primary Breast Tumor in Women
presenting with de novo stage IV Breast Cancer;
Turkish Study (Protocol MF07-01)
![Page 18: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/18.jpg)
Schema
![Page 19: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/19.jpg)
Patients
![Page 20: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/20.jpg)
Patients
• Average age 51 years
• 56-58% Grade 3 : 39-49% T3 and T4, 80% NST
• 65-73% One site of met only
• No Histological confirmation of mets
• 40-52% Bone Only
• 15-24% solitary bone met
• 25% BCS 75% mastectomy
• XRT to mets in 18-30% in both groups
![Page 21: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/21.jpg)
Overall Survival
![Page 22: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/22.jpg)
Overall Survival in ER +ve vs ER –ve Groups
![Page 23: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/23.jpg)
Survival in Different Groups
SURGERY NO SURGERY
Group N/deaths Survival (95% CI) N/deaths Survival (95% CI) p-value
(Log rank
test
Solitary
bone
33/3 61.4(7.7, 91.1) 20/8 44.0(16.5, 68.8) 0.02
![Page 24: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/24.jpg)
Survival in Different Groups
SURGERY NO SURGERY
Group N/deaths Survival (95% CI) N/deaths Survival (95% CI) p-value
(Log rank
test
Solitary
bone
33/3 61.4(7.7, 91.1) 20/8 44.0(16.5, 68.8) 0.02
Solitary
Lung or
Liver
13/4 55.6(8.6, 86.9) 16/3 67.0(26.1, 88.7) 0.65
![Page 25: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/25.jpg)
Survival in Different Groups
SURGERY NO SURGERY
Group N/deaths Survival (95% CI) N/deaths Survival (95% CI) p-value
(Log rank
test
Solitary
bone
33/3 61.4(7.7, 91.1) 20/8 44.0(16.5, 68.8) 0.02
Solitary
Lung or
Liver
13/4 55.6(8.6, 86.9) 16/3 67.0(26.1, 88.7) 0.65
Multiple
lung or liver
9/7 13.3(0.8, 44.1) 11/3 46.7(7.1, 80.3) 0.003
![Page 26: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/26.jpg)
Conclusions
• No improvement in survival with surgery in Stage IV
disease
• Better outcomes in younger (<55y) + solitary vs multiple
bone mets, and with bone vs other mets
• Surgery possibly disadvantageous for visceral and
advantageous for solitary bone mets
• Patients with aggressive phenotypes in particular had
no benefit from surgery
![Page 27: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/27.jpg)
TBRC13: A prospective Analysis of the
Role of Surgery in Stage IV disease
• Prospective Registry Study
• 127 patients - 14 sites:
112 Stage IV intact primary: Cohort A
15 developed mets <3m surgery: Cohort B
• Median Follow up 25 months
King et al Multicenter
![Page 28: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/28.jpg)
Outcomes for 2 Cohorts
Intact Primary
Mets <3 months
![Page 29: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/29.jpg)
Overall Survival: No Effect of Surgery
Cohort B
Cohort A
Non Responders
A Responder
Surgery
A Responder
No Surgery
![Page 30: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/30.jpg)
Ongoing US Trial New Design
New design planned to detect a 19% in survival 30 vs 49% at 3 years
Based on SABCS data this is unrealistsic
![Page 31: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/31.jpg)
Conclusions
• A large benefit from Primary Surgery to the local site
is unlikely in Stage IV disease
• Assumptions for US trial incorrect
Current design unlikely to meet endpoint
• Pooled analyses of all trials may be needed to
determine whether there is a small benefit from
Surgery in Stage IV Breast cancer
![Page 32: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/32.jpg)
![Page 33: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/33.jpg)
Magnetometer and Iron as a Tracer in
SNBx
• 150 patients having SNBx had both radioisotope and
Iron Injected
Thill et al SABCS P1 O1 O2
![Page 34: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/34.jpg)
Results with Magnetometer
Thill et al SABCS P1 O1 O2
• SN Detection rate
146/150 for radio isotope
147/150 for Iron
• Average nodes 1.8 vs 1.9
• Positive nodes
91.2% for radio isotope
95.6% for Iron
• All patients with a involved SLNs would be
Identified by sampling 2 lymph nodes with
Highest magnetic or radioisotope count
• Iron and Magnetometer works and has potential advantages
![Page 35: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/35.jpg)
![Page 36: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/36.jpg)
Post-operative Radiotherapy In
Minimum-risk Elderly – PRIME II
Kunkler IH, Williams LJ, Jack W, Canney P, Prescott RJ, Dixon JM on behalf of the
PRIME II investigators
San Antonio Breast Cancer Symposium, Dec 10-14th, 2013
![Page 37: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/37.jpg)
Aim
To assess the impact on local control of the
omission of postoperative whole breast radiotherapy
after breast conserving surgery and adjuvant
endocrine therapy in ‘low risk’ older patients
![Page 38: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/38.jpg)
Eligibility: Inclusion Criteria
Age ≥ 65 years
Histologically confirmed Unilateral Invasive breast
cancer
Pathology size ≤ 3cm
Breast conserving surgery
Excision margin of ≥1mm on histological assessment
Oestrogen receptor or progesterone receptor positive
Treated with adjuvant endocrine therapy (including
pre-operative neo-adjuvant endocrine therapy)
No axillary node involvement on histological
assessment
Medically suitable to attend for treatment and follow up
Able and willing to give informed consent
![Page 39: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/39.jpg)
Design
1326
WBI*, N=658
No WBI, n=668
* 40 - 50Gy in 15 – 25 #
![Page 40: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/40.jpg)
Population
No Radiotherapy (n=668) Radiotherapy (n=658)
Age Mean (sd) 71.12 (4.96) 70.78 (4.74)
Tumour size N (%)
0-10mm 258 (38.6%) 265 (40.3%)
10.1-20mm 326 (48.8%) 319 (48.5%)
20.1-30mm 84 (12.6%) 74 (11.2%)
Grade N (%)
1 271 (40.9%) 292 (44.4%)
2 368 (55.6%) 352 (54.6%)
3 23 (3.5%) 13 (2.0%)
LVI N (%)
No 631 (95.2%) 628 (95.9%)
Yes 32 (4.8%) 27 (4.1%)
Pre-operative endocrine therapy N (%)
No 608 (90.9%) 598 (91.7%)
Yes 60 (9.1%) 54 (8.3%)
![Page 41: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/41.jpg)
Local control Local recurrence
5 yr actuarial rate
No RT (n=668)
26 4.1%
RT (n=658)
5 1.1%
Total 31
![Page 42: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/42.jpg)
ER status: Effect of RT
Local recurrence/N (%)
ER* No RT RT p-value
High (7-8) 19/594 (3.2%) 5/602 (0.8%) 0.003
Low (2-6) 7/63 (11.1%) 0/54 (0%) 0.015
* High ER is defined as ER+ve, ER≥7, fmol>20, staining>20%, and +++. Anything else is low ER
![Page 43: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/43.jpg)
Multivariate LR
Variable HR (95% CI) p-value
T size (ref 0-10mm)
1
10.1-20mm 0.53 (0.23,1.22)
0.14
20.1-30mm 1.17 (0.43, 3.20)
0.76
Margins (ref >5mm)
1
<1mm 1.99 (0.25, 16.04)
0.52
1-5mm 0.89 (0.40, 1.98)
0.78
Re-excision 1.05 (0.38, 2.89)
0.92
Radiotherapy (ref Yes)
1
No 5.08 (1.95, 13.24)
0.001
![Page 44: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/44.jpg)
Multivariate LR
Variable HR (95% CI) p-value
Age (ref 65-69) 1
70+ 2.08 (0.95, 4.55)
0.07
Grade (ref G1) 1
G2 1.31 (0.59, 2.90)
0.51
G3 3.48 (0.89, 13.65)
0.07
LVI (ref No) 1
Yes 1.28 (0.29, 5.59)
0.75
ER status (ref High)
1
Low 2.84 (1.21, 6.65)
0.02
Variable HR (95% CI) p-value
T size (ref 0-10mm)
1
10.1-20mm 0.53 (0.23,1.22)
0.14
20.1-30mm 1.17 (0.43, 3.20)
0.76
Margins (ref >5mm)
1
<1mm 1.99 (0.25, 16.04)
0.52
1-5mm 0.89 (0.40, 1.98)
0.78
Re-excision 1.05 (0.38, 2.89)
0.92
Radiotherapy (ref Yes)
1
No 5.08 (1.95, 13.24)
0.001
![Page 45: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/45.jpg)
Regional & distant recurrences /
contralateral IBC, new cancers and 5
year actuarial rates
No RT (n=668)
RT (n=658) Total (n=1326)
Regional recurrence
8 3 11
(1.5%) (0.5%)
![Page 46: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/46.jpg)
Regional & distant recurrences /
contralateral IBC, new cancers and 5
year actuarial rates
No RT (n=668)
RT (n=658) Total (n=1326)
Regional recurrence
8 3 11
(1.5%) (0.5%)
Distant recurrence
5 5 10
(1.0%) (0.5%)
![Page 47: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/47.jpg)
Regional & distant recurrences /
contralateral IBC, new cancers and 5
year actuarial rates
No RT (n=668)
RT (n=658) Total (n=1326)
Regional recurrence
8 3 11
(1.5%) (0.5%)
Distant recurrence
5 5 10
(1.0%) (0.5%)
Contra-lateral BC
4 7 11
(0.7%) (1.5%)
![Page 48: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/48.jpg)
Regional & distant recurrences /
contralateral IBC, new cancers and 5
year actuarial rates
No RT (n=668)
RT (n=658) Total (n=1326)
Regional recurrence
8 3 11
(1.5%) (0.5%)
Distant recurrence
5 5 10
(1.0%) (0.5%)
Contra-lateral BC
4 7 11
(0.7%) (1.5%)
New (non-breast) cancer
29 26 55
(4.3%) (3.7%)
![Page 49: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/49.jpg)
Overall survival
Overall survival (deaths)
5 yr actuarial rate
No RT (n=668)
49 93.9%
RT (n=658)
40 93.9%
Total 87
![Page 50: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/50.jpg)
Deaths
Cause No RT (n=668)
RT (n=658) Total
Breast Cancer 8 4 12
BC present but not cause
2 1 3
No Breast Cancer
36 29 65
Cause unknown 4 5 9
Total 50 (7.5%) 39 (5.9%) 89 (6.7%)
Breast cancer deaths 13.5% of all deaths
Deaths without breast cancer: 73.0%
![Page 51: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/51.jpg)
Conclusions
Omission of WBRT in women ≥65 yrs with pN0, HR positive breast cancer after BCS and endocrine therapy results in a 4.1% 5 year IBTR
RT reduces IBTR significantly, absolute reduction very small in HR rich (3.2% vs 0.8%)
Excluding RT does not compromise overall survival
Omission of postoperative WBRT in HR rich patients based on the 5 year rate of IBTR and overall survival appears a reasonable option
![Page 52: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/52.jpg)
![Page 53: San Antonio Breast Cancer Symposium Updatee-syllabus.gotoper.com/_media/_pdf/MBC14_Sun_0945... · Cancer At First Presentation : A Randomized Controlled Trial PI: R A Badwe Professor](https://reader036.fdocuments.us/reader036/viewer/2022080722/5f7b8092583f910f8105a451/html5/thumbnails/53.jpg)
Thank you for your attention